Advertisement
Australia markets closed

  • ALL ORDS

    8,013.80
    +11.00 (+0.14%)
     

  • ASX 200

    7,767.50
    +7.90 (+0.10%)
     

  • AUD/USD

    0.6669
    +0.0018 (+0.27%)
     

  • OIL

    81.46
    -0.28 (-0.34%)
     

  • GOLD

    2,336.90
    +0.30 (+0.01%)
     

  • Bitcoin AUD

    90,740.73
    -1,556.68 (-1.69%)
     

  • CMC Crypto 200

    1,264.98
    -18.85 (-1.47%)
     

  • AUD/EUR

    0.6221
    +0.0015 (+0.24%)
     

  • AUD/NZD

    1.0940
    +0.0013 (+0.12%)
     

  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     

  • NASDAQ

    19,682.87
    -106.16 (-0.54%)
     

  • FTSE

    8,164.12
    -15.56 (-0.19%)
     

  • Dow Jones

    39,118.86
    -45.20 (-0.12%)
     

  • DAX

    18,235.45
    +24.90 (+0.14%)
     

  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     

  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

Business Wire
·1-min read

SOUTH SAN FRANCISCO, Calif., May 29, 2024--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 12:30 pm ET in New York, NY.

A webcast of the panel discussion will be available on the "Events & Presentations" section of the Company’s website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. Kezar’s oncology product candidate, KZR-261, targeting the Sec61 translocon and protein secretion pathway, is being evaluated in an open-label dose-escalation Phase 1 clinical trial to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.

ADVERTISEMENT

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529724497/en/

Contacts

Investor and Media Contact:
Gitanjali Jain
Vice President, Investor Relations and External Affairs
Kezar Life Sciences, Inc.
gjain@kezarbio.com